Despite the small sample sizes of these trials, the study of nivolumab plus ipilimumab demonstrated that ipilimumab was markedly effective in patients with cold tumors, supporting the theory that CTLA-4 blockade might be the most beneficial in patients lacking pre-existing anti-tumor immunity. Here, CTLA4 is linked to neoplasm.